healthbook ASH Virtual 2020 Newsroom

 

Expert Interviews
Prof. Davide Rossi: Highlights in CLL
Prof. Davide Rossi presents his personal highlights from the ASH Virtual Congress 2020 in CLL: Included are his key studies:

  • 123 Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study. Wierda, WG. et al.
  • 125 Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx). Kater, AP. et al.
Video interview with:
Prof. Davide Rossi
Oncology Institute of Southern Switzerland (IOSI)
and Institute of Oncology Research (IOR)
Bellinzona, Switzerland
PD Dr Jeroen S. Goede: Highlights in AML, MM and CLL
PD Dr Jeroen S. Goede presents his personal highlights from the ASH Virtual Congress 2020 in lymphoma and multiple myeloma: Included are his key studies: Acute Myeloid Leukemia

  • 589 Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine. Pratz, KW. et al.
  • 1944 Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study. Pratz, KW. et al.

 Multiple Myeloma

  • 414 Depth of Response and Response Kinetics of Isatuximab plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Interim Analysis Martin, T. et al.
  • 3241 Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: IKEMA Subgroup Analysis. Capra, M. et al.
  • 1411 Isatuximab Plus Pomalidomide and Dexamethasone in Frail Patients with Relapsed/Refractory Multiple Myeloma: ICARIA-MM  Subgroup Analysis. Schjesvold, F. et al

 Chronic Lymphocytic Leukemia

  • 125: Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx). Kater, AP. et al.
Video interview with:
PD Dr Jeroen S. Goede
Cantonal Hospital Winterthur
Winterthur, Switzerland
Prof. Dr Christoph Renner: Highlights in Lymphoma and Multiple Myeloma
Prof. Dr Christoph Renner presents his personal highlights from the ASH Virtual Congress 2020 in lymphoma and multiple myeloma: Included are his key studies:
Lymphoma

  • 39 Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma. Bachy, E. et al.

  • 40 Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL). Ruan, J. et al.

  • 475 PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa Ahl 2011 Phase 3 Study. Casasnovas, O. et al.

  • 470 Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. Moskowitz, AJ. et al.

  • 471 Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients, Yasenchak, CA. et al.

  • 120 Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group. Callanan, MB. et al.

  • 122 Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma – Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible. Jerkeman, M. et al.

  • 401 Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B‑Cell Lymphoma. Olszewski, AJ et al.

  • 125 Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx). Kater, AP. et al.

  • 2103 ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi‑Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL). Kenderian, SS et al.

Multiple Myeloma

  • 549 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. Kaufman, J. et al.

  • 550 Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95). Sonneveld, P. et al.

  • 143 Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial. Perrot, A. et al.

  • 1367 Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis. Berdeja, JV. et al.

  • 177 CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma. Madduri, D. et al.

  • 292 Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. Cohen, AD. et al.

  • 294 Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial. Raab, MS. et al.

Video interview with:
Prof. Dr Christoph Renner
Onkozentrum Zurich
Zurich, Switzerland

 

Prof. Dr John Seymour: Highlights in CLL

healthbook requested Prof. Dr John Seymour to summarize the results of the MURANO trial that was presented at the ASH Virtual Congress 2020.

Prof. John Seymour presents his personal highlights from the ASH Virtual Congress 2020 in chronic lymphocytic leukemia (CLL). Included are his two key studies:

  • 125: Five-Year Analysis of MURANO Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx). Kater, A. et al.

  • 3139: Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration VenR in the MURANO Study.
    Harrup, R et al.

Video interview with:
Prof. Dr John Seymour
Peter MacCallum Cancer Centre,
Royal Melbourne Hospital
Melbourne, Australia

 

Dr Carmen De Ramon Ortiz: Highlights in Multiple Myeloma
Dr Carmen De Ramon presents her personal highlights from the ASH Virtual Congress 2020 in multiple myeloma: Included are her key studies:

  • 177 CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma. Madduri, D. et al.
  • 129 Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma. Mailankody, S. et al.
  • 292 Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. Cohen, AD. et al.
  • 293 Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma. Rodriguez, C. et al.
  • 143 Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial. Perrot, A. et al.
  • 550 Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95). Sonneveld, P. et al.
  • 3243 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin. Vorhees P et al.
  • 549 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. Kaufman J. et al.
  • 412 Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Dimopoulos, MA. et al.
  • 2316 Isatuximab Plus Carfilzomib and Dexamethasone Vs Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IKEMA): Interim Analysis of a Phase 3, Randomized, Open-Label Study. Moreau, P. et al.
  • 414 Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis. Martin, T. et al.
  • 1411 Isatuximab Plus Pomalidomide and Dexamethasone in Frail Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis. Schjesvold, F. et al.
Video interview with:
Dr Carmen De Ramon
Department of Hematology
University Hospital Geneva (HUG)
Geneva, Switzerland

 

Chronic Lymphocytic Leukemia
Dr Othman Al-Sawaf discusses the results of the CLL-14 Trial presented at ASH Virtual Congress 2020.

  • 127: Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL-14 Trial.
Video interview with:
Dr Othman Al-Sawaf
University of Cologne
Cologne, Germany
Myeloproliferative Neoplasms
Dr Jyoti Nangalia discusses the results of her study presented at ASH Virtual Congress 2020:

  • LBA-1: Driver Mutation Acquisition in Utero and Childhood Followed By Lifelong Clonal Evolution Underlie Myeloproliferative Neoplasms.
Video interview with:
Dr Jyoti Nangalia
Wellcome Sanger Institute, Hinxton
University of Cambridge
Wellcome-MRC Cambridge Stem Cell Institute
United Kingdom Cambridge Universities NHS Trust, Cambridge, United Kingdom
Acute Leukemia
Dr Lindsey Montefiori discusses the results of her study presented at the ASH Virtual Congress 2020:

  • LBA-3: Enhancer Hijacking of BCL11B Defines a Subtype of Lineage Ambiguous Acute Leukemia.
Video interview with:
Dr Lindsey Montefiori
Department of Pathology
St. Jude Children’s Research Hospital
Memphis, TN, USA
Chronic Myeloid Leukemia
Dr Diletta Fontana discusses the results of his study presented at the ASH Virtual Congress 2020:

  • LBA-5: ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine.
Video interview with:
Dr Diletta Fontana
Department of Medicine and Surgery
University of Milano – Bicocca
Monza, Italy
Hemophilia B
Prof. Dr Steven W. Pipe discusses the results of his study presented at ASH Virtual Congress 2020:

  • LBA6: First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies
Video interview with:
Prof. Dr Steven W. Pipe
Department of Pathology
Michigan Medicine
University of Michigan, Ann Arbor, MI, USA
Study Highlights

Immune Thrombocytopenia
LBA-2: Frontline mycophenolate plus corticosteroid is effective and safe in patients with immune thrombocytopenia
Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by increased risk for bleeding and fatigue. Current first-line ITP treatment includes high-dose corticosteroids but only about 20% of patients achieve sustained long-term remission. The FLIGHT trial investigated the efficacy of first-line mycophenolate (MMF) in combination with corticosteroid versus corticosteroid alone in patients with ITP.
Read more

Reference: Bradbury CA et al. 2020. A Multicentre Randomised Trial of First Line Treatment Pathways for Newly Diagnosed Immune Thrombocytopenia: Standard Steroid Treatment Versus Combined Steroid and Mycophenolate. the Flight Trial. Oral presentation presented at: ASH 2020; 5−8 December 2020.

Chronic Myeloid Leukemia
LBA-4: ASCEMBL: Asciminib significantly improved major molecular response compared with bosutinib in pretreated patients with CML in the chronic phase
Asciminib, a first-in-class STAMP inhibitor with a new mechanism of action, has been investigated in adult patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase III ASCEMBL trial. At ASH 2020, Prof. Hochhaus presented the efficacy and safety results of the study.
Read more

Reference: Hochhaus A et al. 2020. Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs). Oral presentation presented at: ASH 2020; 5−8 December 2020.

 

Hemophilia B
LBA-6: HOPE-B: Etranacogene dezaparvovec is effective and safe in severe hemophilia B patients
The single-arm, multinational, phase III Hope-B trial investigated the efficacy and safety of etranacogene dezaparvovec, an adeno-associated virus serotype 5 (AAV5) viral vector carrying a gene cassette with the Padua variant of Factor IX (FIX-Padua), in adult males (mean age 41.5 years) with severe or moderate-severe hemophilia B (HB) with a wide range of pre-existing neutralizing antibodies (NAbs) to AAV5 vector at baseline.
Read more

Reference: Pipe SW et al. 2020. First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies. Oral presentation presented at: ASH 2020; 5−8 December 2020.

Classical Hodgkin’s lymphoma
ECHELON-1: Frontline brentuximab vedotin plus chemotherapy provide long-term efficacy in patients with cHL
The phase III ECHELON-1 study showed that treatment with brentuximab vedotin, doxorubicin, vinblastine and dacarbazine (A+AVD) led to sustained improvement in modified progression-free survival (PFS) in patients with previously untreated stage III/IV classical Hodgkin’s lymphoma (cHL), as compared with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD).
Read more

Reference: Straus DJ et al. 2020. Brentuximab vedotin with chemotherapy for patients with previously untreated, stage III/IV classical Hodgkin lymphoma: 5-year update of the ECHELON-1 study. Poster presentation presented at: ASH 2020; 5−8 December 2020.

Peripheral T-Cell Lymphoma
ECHELON-2: 5-year results show that brentuximab vedotin plus chemotherapy continues to outperform CHOP in patients with CD30-expressing peripheral T-cell lymphoma
In the phase III ECHELON-2 study, frontline brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP) was superior to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with CD30-expressing peripheral T-cell lymphoma (PTCL).
Read more

Reference: Horwitz S et al. 2020. The ECHELON-2 trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-Cell lymphoma. Poster presentation presented at: ASH 2020; 5−8 December 2020.

Chronic Lymphocytic Leukemia
MURANO: 5-year data demonstrate sustained clinical benefit of fixed-duration venetoclax plus rituximab in patients with relapsed/refractory CLL
The randomized, phase III MURANO study showed that at 48-month follow-up, deep responses with undetectable minimal residual disease (uMRD) were associated with superior progression-free survival (PFS) in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) treated with fixed-duration venetoclax plus rituximab (VenR) compared with bendamustine plus rituximab (BR).
Read more

Reference: Kater AP et al. 2020. Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx). Oral presentation presented at: ASH 2020; 5−8 December 2020.

Chronic Lymphocytic Leukemia
CLL-14: Effective MRD eradication in newly diagnosed CLL patients treated with fixed-duration venetoclax plus obinutuzumab
Minimal residual disease (MRD) is an established surrogate marker of clinical outcomes during and after treatment of chronic lymphocytic leukemia (CLL).
Read more

Reference: Al-Sawaf O et al. 2020. Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial. Oral presentation presented at: ASH 2020; 5−8 December 2020.

Acute Myeloid Leukemia
Magrolimab is well-tolerated with promising efficacy in newly diagnosed AML patients, regardless of TP53-mutation status
Magrolimab is an anti-CD47 antibody and macrophage checkpoint inhibitor that blocks the “don’t eat me” signal used by cancer cells. At ASH 2020, Dr Sallman presented updated results from the phase Ib study that investigated magrolimab in combination with azacitidine (AZA) in untreated AML patients, including those with TP53-mutant AML.
Read more

Reference: Sallman D et al. 2020. The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results. Oral presentation presented at: ASH 2020; 5−8 December 2020.

Multiple Myeloma
IKEMA: The addition of isatuximab to carfilzomib and dexamethasone demonstrated a clinically meaningful improvement in the depth of response in relapsed multiple myeloma patients
The randomized, phase III IKEMA trial aimed to investigate the triplet therapy of isatuximab (Isa), carfilzomib (K), and dexamethasone (d) in patients with relapsed multiple myeloma (MM). A total of 302 patients who had previously received 1−3 prior lines of therapy were randomized 3:2 to receive either Isa-Kd (n=179) or Kd (n=123).
Read more

Reference: Martin T et al. 2020. Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis. Oral presentation presented at: ASH 2020; 5−8 December 2020.

Acute Myeloid Leukemia
VIALE-A and VIALE-C: Venetoclax-based therapy imparts meaningful health-related quality of life benefits in older AML patients
The randomized phase III VIALE-A and VIALE-C trials included treatment-naïve adult patients with acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy. Interestingly both, VIALE-A and VIALE-C demonstrated that venetoclax-based combination therapies were associated with improved survival in older AML patients.
Read more

Reference: Pratz KW et al. 2020. Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine. Oral presentation presented at: ASH 2020; 5−8 December 2020.

Acute Lymphoblastic Leukemia
Pegaspargase re-challenge in children and adolescents with ALL
At ASH 2020, Dr Vrooman presented the results of the prospective DFCI 16-001 study, which piloted re-challenging patients with pegaspargase after initial grade 2 hypersensitivity to this agent, with premedication at re-challenge and assessment of serum asparaginase activity (SAA).
Read more

Reference: Vrooman et al. 2020. Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001. Oral presentation presented at: ASH 2020; 5−8 December 2020.